## Edgar Filing: CLEVELAND BIOLABS INC - Form 4

CLEVELAN Form 4 June 21, 2013	D BIOLABS INC	2									
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549									PPROVAL 3235-0287 January 31,		
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). STATEMENT OF CHANGES IN BENEFICIAL ( SECURITIES Filed pursuant to Section 16(a) of the Securities Excl Section 17(a) of the Public Utility Holding Company A 30(h) of the Investment Company Act of 1(b).						chang Act of	DWNERSHIP OF Estimated ave burden hours response tange Act of 1934, ct of 1935 or Section				
(Print or Type R	Responses)										
1. Name and Address of Reporting Person <u>*</u> BROWN JULIA R			2. Issuer Name and Ticker or Trading Symbol CLEVELAND BIOLABS INC [CBLI]				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
(Last) C/O CLEVE INC., 73 HI	3. Date of Earliest Transaction (Month/Day/Year) 06/19/2013				X_ Director 10% Owner Officer (give title Other (specify below)						
Filed(				. If Amendment, Date Original iled(Month/Day/Year)				<ul> <li>6. Individual or Joint/Group Filing(Check</li> <li>Applicable Line)</li> <li>_X_ Form filed by One Reporting Person</li> <li> Form filed by More than One Reporting</li> </ul>			
BUFFALO,								Person		porting	
(City)	(State) (	(Zip)	Table	e I - Non-D	erivative S	ecurit	ies Acq	uired, Disposed o	f, or Beneficial	lly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	Execution any		Code (D)			of	5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Indirect	
a				Code V	Amount	or (D)	Price	(Instr. 3 and 4)			
Common Stock, par value \$0.005 per share	06/19/2013			A	15,939 (1)	A	\$ 0	15,939	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

## Edgar Filing: CLEVELAND BIOLABS INC - Form 4

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Transact Code (Instr. 8)	5. ionNumber of Derivativ Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	;	ate	Secur	unt of rlying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secur Bene Owne Follo Repo Trans (Instr
			Code V	′ (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

## **Reporting Owners**

<b>Reporting Owner Name / Address</b>	Relationships					
reporting o when runne / runness	Director	10% Owner	Officer	Other		
BROWN JULIA R C/O CLEVELAND BIOLABS, INC. 73 HIGH STREET BUFFALO, NY 14203	Х					
Signatures						
/s/ Leah Brownlee, Attorney-in-fact fo Brown	06/21/2013					
<u>**</u> Signature of Reporting Person			Date			

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Dalationali

(1) The reporting person received a portion of her annual cash fees for services to be performed in 2013 as a member of the Board of Directors in shares of the Issuer's common stock.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.